Market Outlook: Injectable Drug Delivery Industry to Top US$1,034.78 Billion by 2030

Prominent players in the injectable drug delivery market are Johnson & Johnson Services, Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), Pfizer Inc. (US), Merck & Co., Inc. (US), Novartis AG (Switzerland), Cardinal Health (US), BD (US), Baxter (US), B. Braun SE (Germany), and Terumo Corporation (Japan).
The global injectable drug delivery market, valued at US$633.77 billion in 2024, stood at US$690.23 billion in 2025 and is projected to advance at a resilient CAGR of 8.4% from 2025 to 2030, culminating in a forecasted valuation of US$1,034.78 billion by the end of the period.

Download PDF Brochure: [https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=150&utm_source=abnewswire.com&utm_medium=paidpr&utm_campaign=injectabledrugdeliverymarket]

By Based on products, the formulations segment accounted for the largest market share in 2024, primarily due to the increased use of biologics. The rising prevalence of chronic diseases such as cancer, HIV, and obesity further fuels the growth of this market. The parenteral route of drug administration is considered ideal for biologics, as it enhances the bioavailability of therapeutic agents and maintains their stability. Additionally, a strong focus on research and development for targeted and controlled drug delivery drives market expansion. Long-acting and sustained-release formulations reduce dosing frequency, improving patient compliance. Innovations in injectable drug formulations, including the use of nanoparticles, micelles, and liposomes for targeted drug delivery, also contribute to market growth.

By formulation packaging, the ampoules segment is projected to grow at the highest CAGR within the formulation packaging sector. This growth can be attributed to the numerous advantages ampoules offer over other packaging options, such as vials. Ampoules are typically designed for single use, significantly reducing the risk of cross-contamination and ensuring accurate therapeutic product dosages. Additionally, they are more cost-effective than prefilled syringes, cartridge-based packaging, and vials. Glass ampoules are compatible with a wide range of therapeutic agents, including biologics, and help maintain their stability. Moreover, ampoules provide a longer shelf life for drugs and are easy to store.

By therapeutic application, the rapid growth of the obesity market segment is driven by the sedentary lifestyle of people worldwide. The high consumption of over-processed foods and various environmental factors significantly contribute to this trend. Additionally, genetic predisposition plays a role in the prevalence of this chronic condition.

Recent advancements in self-administration devices, such as autoinjectors and wearable technology, have made it easier for individuals to administer medication, especially in emergency situations. These devices provide options for at-home care, improving patient compliance. Furthermore, long-acting injectable formulations reduce the frequency of required medication dosages.

By site of administration, the dermal segment accounted for the largest market share in 2024. This segment encompasses both intradermal and subcutaneous routes of administration. The significant market share can be attributed to the ease of dermal-based administration, which is less invasive than intravenous routes. Dermal administration is also less painful and is typically preferred by patients who require frequent dosing for chronic conditions.

The subcutaneous route is particularly well-suited for self-administration devices, such as autoinjectors and pen injectors. In addition, needle-free injectors and microneedle devices are being developed for intradermal administration, which enhances patient compliance. Dermal-based injections are appropriate for a wide range of therapeutic products, including biologics, insulin, and vaccines.

North America holds the largest share of the injectable drug delivery market, primarily due to a high burden of chronic conditions such as diabetes, cancer, and rheumatoid arthritis. The region's well-established healthcare infrastructure, early adoption of biologics, and strong reimbursement policies significantly contribute to market growth. The US has a robust regulatory framework and a high concentration of pharmaceutical and biotechnology firms investing in advanced injectable therapies.

Request Sample Pages : [https://www.marketsandmarkets.com/requestsampleNew.asp?id=150&utm_source=abnewswire.com&utm_medium=paidpr&utm_campaign=injectabledrugdeliverymarket]

Prominent players in the injectable drug delivery market are Johnson & Johnson Services, Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), Pfizer Inc. (US), Merck & Co., Inc. (US), Novartis AG (Switzerland), Cardinal Health (US), BD (US), Baxter (US), B. Braun SE (Germany), and Terumo Corporation (Japan).

Media Contact
Company Name: MarketsandMarkets Trademark Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=market-outlook-injectable-drug-delivery-industry-to-top-us103478-billion-by-2030]
Phone: 18886006441
Address:1615 South Congress Ave. Suite 103, Delray Beach, FL 33445
City: Florida
State: Florida
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/injectable-drug-delivery-market-150.html

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.